EA201101302A1 - Фармацевтические комбинации, содержащие rdea119/bay 869766, для лечения специфических злокачественных новообразований - Google Patents

Фармацевтические комбинации, содержащие rdea119/bay 869766, для лечения специфических злокачественных новообразований

Info

Publication number
EA201101302A1
EA201101302A1 EA201101302A EA201101302A EA201101302A1 EA 201101302 A1 EA201101302 A1 EA 201101302A1 EA 201101302 A EA201101302 A EA 201101302A EA 201101302 A EA201101302 A EA 201101302A EA 201101302 A1 EA201101302 A1 EA 201101302A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical combinations
combinations containing
cancer
rdea119
normalizations
Prior art date
Application number
EA201101302A
Other languages
English (en)
Inventor
Марк С. Чэпмен
Original Assignee
Арди Байосайенсиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42135921&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201101302(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Арди Байосайенсиз, Инк. filed Critical Арди Байосайенсиз, Инк.
Publication of EA201101302A1 publication Critical patent/EA201101302A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к области онкологии и обеспечивает композиции и методы лечения специфических злокачественных новообразований, включая немелкоклеточный рак легких, рак молочной железы, рак щитовидной железы, рак поджелудочной железы, рак ободочной кишки, меланому, гепатому и аденокарциному. В частности, описаны композиции и способы, включающие введение, либо одновременное, либо последовательное, фармацевтических комбинаций, содержащих (S)-N-(3,4-дифтор-2-(2-фтор-4-йодфениламино)-6-метоксифенил)-1-(2,3-дигидроксипропил)циклопропан-1-сульфонамид с другими соединениями, пациентам, страдающим от злокачественного новообразования.
EA201101302A 2009-03-11 2010-03-11 Фармацевтические комбинации, содержащие rdea119/bay 869766, для лечения специфических злокачественных новообразований EA201101302A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15940309P 2009-03-11 2009-03-11
PCT/US2010/027060 WO2010105110A1 (en) 2009-03-11 2010-03-11 Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers

Publications (1)

Publication Number Publication Date
EA201101302A1 true EA201101302A1 (ru) 2012-05-30

Family

ID=42135921

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201101302A EA201101302A1 (ru) 2009-03-11 2010-03-11 Фармацевтические комбинации, содержащие rdea119/bay 869766, для лечения специфических злокачественных новообразований

Country Status (23)

Country Link
US (2) US8673876B2 (ru)
EP (1) EP2405908B1 (ru)
JP (2) JP5767122B2 (ru)
KR (1) KR20110132371A (ru)
CN (2) CN102421427B (ru)
AU (1) AU2010224044A1 (ru)
BR (1) BRPI1009448A2 (ru)
CA (2) CA2754913C (ru)
CL (1) CL2011002233A1 (ru)
CO (1) CO6430423A2 (ru)
CR (1) CR20110479A (ru)
CU (1) CU20110170A7 (ru)
DO (1) DOP2011000282A (ru)
EA (1) EA201101302A1 (ru)
EC (1) ECSP11011314A (ru)
HK (2) HK1169603A1 (ru)
IL (1) IL214749A0 (ru)
MA (1) MA33091B1 (ru)
MX (1) MX2011009498A (ru)
PE (1) PE20120105A1 (ru)
SG (1) SG174272A1 (ru)
TN (1) TN2011000455A1 (ru)
WO (1) WO2010105110A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
NZ592338A (en) 2008-09-26 2012-11-30 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
WO2013001372A2 (en) * 2011-06-30 2013-01-03 University Of Oslo Methods and compositions for inhibition of activation of regulatory t cells
US20150132301A1 (en) * 2011-12-09 2015-05-14 Oncomed Pharmaceuticals, Inc. Combination Therapy for Treatment of Cancer
EP2916859B1 (en) 2012-11-02 2017-06-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
US9359444B2 (en) 2013-02-04 2016-06-07 Oncomed Pharmaceuticals Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
EP2848246A1 (en) * 2013-09-13 2015-03-18 Bayer Pharma Aktiengesellschaft Pharmaceutical compositions containing refametinib
DK3043778T3 (da) * 2013-09-13 2017-11-27 Bayer Pharma AG Farmaceutiske sammensætninger, der indeholder refametinib

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925958D0 (en) * 1999-11-02 1999-12-29 Bundred Nigel J Therapeutic use
US6822001B2 (en) * 2000-11-03 2004-11-23 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
US20040191254A1 (en) 2001-10-09 2004-09-30 Fagin James Alexander Method of treatment of thyroid cancer
EA200501676A1 (ru) 2003-04-25 2006-04-28 Джилид Сайэнс, Инк. Фосфонатсодержащие ингибиторы киназы (варианты), способ их получения, фармацевтическая композиция, лекарственная форма на их основе и способ ингибирования киназы у млекопитающего (варианты)
ES2426007T3 (es) 2004-12-17 2013-10-18 Smithkline Beecham (Cork) Limited Método para el tratamiento del cáncer
US20060211074A1 (en) * 2005-01-12 2006-09-21 Boyce James P Kinase-directed, activity-based probes
US20090047365A1 (en) * 2005-02-28 2009-02-19 Eisai R & D Management Co., Ltd. Novel Concomitant Use of Sulfonamide Compound with Anti-Cancer Agent
PL1912636T3 (pl) 2005-07-21 2015-02-27 Ardea Biosciences Inc N-(aryloamino)sulfonamidowe inhibitory mek
US8101799B2 (en) * 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US8329421B2 (en) 2007-07-13 2012-12-11 Ventana Medical Systems, Inc. Methods of predicting response of a neoplasm to an EGFR inhibitor and detecting interactions between EGFR and an EGFR regulatory protein
UA99731C2 (ru) * 2007-07-30 2012-09-25 Ардеа Биосайенсис, Инк Кристаллические полиморфные формы n-(ариламино)сульфонамидов как ингибиторы мэк, композиция (варианты) и применение
CN103479604B (zh) * 2007-07-30 2016-08-10 阿迪生物科学公司 作为mek抑制剂的包括多晶型物的n-(芳氨基)磺酰胺衍生物和组合物、其使用方法和制备方法
US8044240B2 (en) * 2008-03-06 2011-10-25 Ardea Biosciences Inc. Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof
DE102008031039A1 (de) 2008-06-30 2009-12-31 Dömling, Alexander, Priv.-Doz. Dr. Tarceva zur Anwendung in der Organtransplantation.

Also Published As

Publication number Publication date
CO6430423A2 (es) 2012-04-30
US20120071435A1 (en) 2012-03-22
JP2012520321A (ja) 2012-09-06
CA2754913A1 (en) 2010-09-16
AU2010224044A1 (en) 2011-09-22
JP5767122B2 (ja) 2015-08-19
ECSP11011314A (es) 2011-10-31
CR20110479A (es) 2011-10-24
TN2011000455A1 (en) 2013-03-27
MA33091B1 (fr) 2012-03-01
BRPI1009448A2 (pt) 2016-03-01
CN103948600A (zh) 2014-07-30
JP2014237716A (ja) 2014-12-18
DOP2011000282A (es) 2011-10-15
US9220696B2 (en) 2015-12-29
CU20110170A7 (es) 2012-06-21
EP2405908A1 (en) 2012-01-18
IL214749A0 (en) 2011-11-30
CL2011002233A1 (es) 2012-02-03
KR20110132371A (ko) 2011-12-07
PE20120105A1 (es) 2012-02-22
CA2972379A1 (en) 2010-09-16
WO2010105110A1 (en) 2010-09-16
CA2754913C (en) 2017-08-22
HK1199710A1 (en) 2015-07-17
SG174272A1 (en) 2011-10-28
CN102421427A (zh) 2012-04-18
MX2011009498A (es) 2011-10-14
HK1169603A1 (en) 2013-02-01
CN102421427B (zh) 2013-11-06
JP5911929B2 (ja) 2016-04-27
US20140080783A1 (en) 2014-03-20
EP2405908B1 (en) 2016-12-21
US8673876B2 (en) 2014-03-18

Similar Documents

Publication Publication Date Title
EA201101302A1 (ru) Фармацевтические комбинации, содержащие rdea119/bay 869766, для лечения специфических злокачественных новообразований
EA201590941A1 (ru) Гетероциклические ингибиторы глютаминазы
EA201591145A1 (ru) Ингибиторы гистондеметилазы
EA201391604A1 (ru) Способ лечения рака и раковой боли в костях
MX350788B (es) Compuestos de carbamato y preparación y uso de los mismos.
EA201171195A8 (ru) Конъюгаты, частицы, композиции "полимер-агент" и способы их применения
EA201590535A1 (ru) Способы лечения локально прогрессирующего запущенного рака молочной железы
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
MX344530B (es) Compuestos de benceno substituido.
EA201290901A1 (ru) Фитоканнабиноиды для лечения злокачественной опухоли
MY162146A (en) Pharmaceutical composition
MY157124A (en) Substituted imidazopyridinyl-aminopyridine compounds
EA201390682A1 (ru) Спирооксиндольные антагонисты mdm2
MX2013015006A (es) Compuestos imidazopiridinil-aminopiridina substituidos.
EA201100136A1 (ru) 2,4'-бипиридинилы в качестве ингибиторов протеинкиназы d, применимые для лечения сердечной недостаточности и рака
IN2014DN11205A (ru)
EA201491265A1 (ru) Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
EA201300610A1 (ru) Хиназолинкарбоксамидазетидины
EA201792103A1 (ru) Композиции и способы для ингибирования экспрессии генов hif2альфа
MX336761B (es) Compuestos para el tratamiento de cancer.
EA201100296A1 (ru) Новые фениламино-изоникотинамидные соединения
RU2013131241A (ru) Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака
EA201000141A1 (ru) Новые триазены для лечения рака
EA201991069A1 (ru) Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом
WO2012129517A3 (en) Evaluating protein expression in patient stratification and other therapeutic, diagnostic and prognostic methods for cancer